Comments
Sun Pharmaceutical Industries today reported a 75.17 per cent decline in its consolidated net profit at Rs 365.39 crore for the December quarter, impacted by a one-time deferred tax adjustment of Rs 513 crore related to changes in US tax rates.
The drug major had posted a net profit of Rs 1,471.82 crore in the October-December period of 2016-17.
Its total revenue from operations stood at Rs 6,653.23 crore during the third quarter of 2017-18. It was Rs 7,925.11 crore during the same period of the previous fiscal.
“Our Q3 performance reflects a gradual improvement in profitability over the first half of this year, despite a challenging US generic pricing environment,” Sun Pharma Managing Director Dilip Shanghvi said in a statement.
In the US market, company said its sales declined by 35 per cent during the quarter at $ 328 million and accounted for 32 per cent of total sales.
“This decline was driven by the overall pricing pressure in the US generics market and the YoY reduction in sales of generic Imatinib and Olmesartan authorised generics,” it added.
In India, sales of branded formulations stood at Rs 2,085 crore, up 6 per cent from previous fiscal and accounting for 32 per cent of total sales, Sun Pharma said.
“Our sales in emerging markets were at $ 189 million for third quarter; a growth of 10 per cent compared to the same quarter last year,” it added.
Scrip dips
Sun Pharmaceutical shares today fell nearly 3 per cent after the company reported 75 per cent dip in its consolidated net profit for the third quarter ended December 2017.
The stock dipped 2.80 per cent to settle at Rs 572.65 on NSE. During the day, it touched a high of Rs 591.80 and a low of Rs 571.20.
On BSE, shares of the company ended the day at Rs 574.45, down 2.53 per cent from the previous close. The stock had touched a high of Rs 593.90 and a low of Rs 570 in intra-day trade.
On the equity volume front, 66.30 lakh shares of the firm were traded on NSE while 7.28 lakh scrips changed hands on BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.